GlassScriptPhysician profile
Vinutha N Ravi
NPI 1518946045
$12,289.28
in general payments reported to CMS, 2019-2025
58 companies · $1,814 in 2025
The $1,814 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,420 · 2020: $989 · 2021: $1,968 · 2022: $2,169 · 2023: $1,625 · 2024: $2,304 · 2025: $1,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,543 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,543.09 |
| Education | $199.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,111.38 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $931.52 | 2021-2025 | |
| Ucb, INC. | $877.77 | 2019-2025 | Rystiggo, Briviact, Fintepla |
| Biogen, INC. | $841.77 | 2019-2025 | Vumerity, Leqembi, Tysabri |
| Novartis Pharmaceuticals Corporation | $785.18 | 2019-2025 | |
| Merz Pharmaceuticals, LLC | $611.63 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Celgene Corporation | $464.66 | 2022-2025 | Zeposia |
| Neurelis, INC. | $441.80 | 2020-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $426.26 | 2019-2025 | Ultomiris |
| Eisai INC. | $401.79 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $397.05 | 2019-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $387.92 | 2019-2025 | Austedo Xr, Austedo Xr |
| Sk Life Science, INC. | $365.05 | 2020-2025 | Xcopri |
| Acadia Pharmaceuticals INC | $342.34 | 2019-2024 | Daybue, Nuplazid |
| Argenx US, INC. | $310.64 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinutha Ravi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.